
## Tarah J Ballinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5648779/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Subtyping of tripleâ€negative breast cancer: Implications for therapy. Cancer, 2015, 121, 8-16.	4.1	280
2	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology, 2020, 38, 4274-4282.	1.6	276
3	Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer. JAMA Oncology, 2020, 6, 1410.	7.1	161
4	Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer. Frontiers in Oncology, 2018, 8, 308.	2.8	62
5	Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy. Clinical Breast Cancer, 2015, 15, 171-180.	2.4	35
6	BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 345-355.	1.6	23
7	Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Research and Treatment, 2014, 145, 389-399.	2.5	20
8	Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. Clinical Cancer Research, 2017, 23, 3520-3528.	7.0	19
9	Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC. Clinical Cancer Research, 2021, 27, 5810-5817.	7.0	19
10	Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Research and Treatment, 2018, 172, 445-452.	2.5	16
11	How we manage <scp>JAK</scp> inhibition in allogeneic transplantation for myelofibrosis. European Journal of Haematology, 2015, 94, 115-119.	2.2	14
12	Discerning the clinical relevance of biomarkers in early stage breast cancer. Breast Cancer Research and Treatment, 2017, 164, 89-97.	2.5	9
13	A Personalized, Dynamic Physical Activity Intervention Is Feasible and Improves Energetic Capacity, Energy Expenditure, and Quality of Life in Breast Cancer Survivors. Frontiers in Oncology, 2021, 11, 626180.	2.8	7
14	Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 3235-3241.	7.0	6
15	Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158. Clinical Cancer Research, 2021, 27, 1195-1199.	7.0	5
16	Impact of African ancestry on the relationship between body mass index and survival in an earlyâ€stage breast cancer trial (ECOGâ€ACRIN E5103). Cancer, 2022, 128, 2174-2181.	4.1	5
17	Patientâ€reported outcomes in the Translational Breast Cancer Research Consortium. Cancer, 2020, 126, 922-930.	4.1	4
18	Landmark trials in the medical oncology management of metastatic breast cancer. Seminars in Oncology, 2021, 48, 246-258.	2.2	4

TARAH J BALLINGER

#	Article	IF	CITATIONS
19	Evaluation of an Extended-duration Chemoprophylaxis Regimen for Venous Thromboembolism after Microsurgical Breast Reconstruction. Plastic and Reconstructive Surgery - Global Open, 2021, 9, e3741.	0.6	4
20	Triple Negative Breast Cancer—Review of Current and Emerging Therapeutic Strategies. Oncology & Hematology Review, 2016, 12, 89.	0.2	3
21	Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer. Contemporary Clinical Trials, 2020, 98, 106168.	1.8	1
22	Impact of Genetic Ancestry on Treatment Toxicity and Racial Disparities in Breast Cancer. Current Breast Cancer Reports, 2020, 12, 161-167.	1.0	1
23	Cancer-Associated Muscle Dysfunction. , 2020, , 379-389.		0
24	Abstract PD9-10: BRE12-158: A post-neoadjuvant, randomized phase 2 trial of personalized therapy vs. treatment of physician's choice for patients with residual triple negative breast cancer. Cancer Research, 2022, 82, PD9-10-PD9-10.	0.9	0
25	Reply to K. Nozawa et al. Journal of Clinical Oncology, 2022, , JCO2200288.	1.6	0